Zynerba Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Armando Anido
Algemeen directeur
US$1.9m
Totale compensatie
| Percentage CEO-salaris | 33.6% |
| Dienstverband CEO | 9yrs |
| Eigendom CEO | 1.9% |
| Management gemiddelde ambtstermijn | 6.8yrs |
| Gemiddelde ambtstermijn bestuur | 8.2yrs |
Recente managementupdates
Recent updates
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?
Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 11Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome
Oct 06Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01
Aug 10We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Jul 22Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital
Jul 21Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation
Mar 23We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
Dec 02We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth
May 27Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome
Dec 17Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?
Nov 23
Zynerba Pharmaceuticals EPS beats by $0.12
Nov 09Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback
Oct 29Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$2m | US$633k | -US$35m |
| Sep 30 2022 | n/a | n/a | -US$36m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$38m |
| Dec 31 2021 | US$2m | US$603k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$37m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$1m | US$585k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$45m |
| Mar 31 2020 | n/a | n/a | -US$36m |
| Dec 31 2019 | US$1m | US$568k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$36m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$2m | US$568k | -US$40m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$41m |
| Mar 31 2018 | n/a | n/a | -US$37m |
| Dec 31 2017 | US$2m | US$552k | -US$32m |
| Sep 30 2017 | n/a | n/a | -US$31m |
| Jun 30 2017 | n/a | n/a | -US$28m |
| Mar 31 2017 | n/a | n/a | -US$26m |
| Dec 31 2016 | US$901k | US$536k | -US$23m |
Compensatie versus markt: De totale vergoeding ($USD 1.88M ) Armando } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).
Compensatie versus inkomsten: De vergoeding van Armando is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Armando Anido (65 yo)
9yrs
Tenure
US$1,881,402
Compensatie
Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 9yrs | US$1.88m | 1.94% $ 1.3m | |
| President | 9yrs | US$1.38m | 1.18% $ 775.1k | |
| CFO & VP of Corporate Development (Leave of Absence) | 7.1yrs | US$1.26m | 0.75% $ 491.5k | |
| VP, Corporate Controller & Interim CFO | 6.6yrs | geen gegevens | 0.17% $ 111.2k | |
| Chief Legal Officer & Corporate Secretary | 1.7yrs | geen gegevens | 0.45% $ 295.1k | |
| Vice President of Human Resources | 5.6yrs | geen gegevens | geen gegevens |
6.8yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ZYNE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 9yrs | US$1.88m | 1.94% $ 1.3m | |
| Independent Director | 8.2yrs | US$107.50k | 0.15% $ 98.5k | |
| Independent Director | 8.2yrs | US$105.00k | 0.15% $ 98.5k | |
| Lead Independent Director | 8.2yrs | US$135.00k | 0.15% $ 98.5k | |
| Independent Director | 5.5yrs | US$102.50k | 0.16% $ 105.0k | |
| Independent Director | 8.2yrs | US$110.00k | 0.15% $ 98.5k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 8yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 7yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.7yrs | US$100.00k | 0.15% $ 98.5k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
8.2yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ZYNE wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).